Kinetics of Microparticles Under Chemotherapy in Patients With Gastric or Pancreatic Cancer
NCT ID: NCT03471468
Last Updated: 2020-02-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
NA
3 participants
INTERVENTIONAL
2018-07-23
2020-01-02
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Our study focuses on the kinetics of microparticles under chemotherapy in patients with pancreatic or gastric cancer by serial measurements of microparticles procoagulant activity.
Detailed Description:
The impact of chemotherapy on microparticles expression will be assessed by measuring their procoagulant activity on blood samples taken during the course of chemotherapy. The thrombotic risk will be evaluated by the score of Khorana in parallel. Microparticles expression in patients with thrombosis will be compared to that in other patients.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site
NCT03498521
Evaluation of Carboplatin Plus Gemcitabine Followed by Concomitant Chemoradiation for Non-resectable Stage III NSCLC
NCT00463515
Carboplatin and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Breast Cancer
NCT00470249
Gemcitabine and Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
NCT00006117
Pemetrexed and Gemcitabine in Patients With Advanced Head and Neck Cancer
NCT00394147
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
kinetics of microparticles under chemotherapy
kinetics of microparticles under chemotherapy in patients with pancreatic or gastric cancer by serial measurements of microparticles procoagulant activity.
kinetics of microparticles under chemotherapy
Blood samples done before chemotherapy and 6 hours later for each of six chemotherapies required by the protocol.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
kinetics of microparticles under chemotherapy
Blood samples done before chemotherapy and 6 hours later for each of six chemotherapies required by the protocol.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Confirmed diagnosis of pancreatic cancer or gastric cancer
* Free subject, without guardianship or trusteeship or subordination
* Patient benefiting from a social security scheme or benefiting through a third party
* Consent given by the patient after clear and fair information about the study
Exclusion Criteria
* Life expectancy ≤10days
* Deep vein thrombosis ou pulmonary embolism ≤3months
* Patient unable to receive chemotherapy (sepsis, acute coronary syndrome, recent stroke, heparin-induced thrombocytopenia, disseminated intravascular coagulation)
* Person enjoying enhanced protection, namely minors, persons deprived of their liberty by a judicial or administrative decision, persons staying in a health or social institution, adults under legal protection, and finally patients in emergency situations
* Pregnant or lactating woman and woman of childbearing age lacking effective contraception
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Poitiers University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU of Poitiers
Poitiers, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DOMICA
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.